Tests IBR854 with pazopanib against pazopanib alone in advanced kidney cancer

Trial details

Who runs it

Imbioray (Hangzhou) Biomedicine Co., Ltd.

Trial code

NCT07087158

Record updated

5 November 2026

Original description

This is a multicenter, randomized, open-label, active-controlled Phase II clinical study evaluating the efficacy and safety of IBR854 combined with Pazopanib versus Pazopanib in Advanced Renal Cell Carcinoma.Read full original descriptionShow less

A Multicenter, Randomized, Open-Label, Active-Controlled Phase II Study Evaluating the Efficacy and Safety of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma

This is a multicenter, randomized, open-label, active-controlled Phase II clinical study evaluating the efficacy and safety of IBR854 combined with Pazopanib versus Pazopanib in Advanced Renal Cell Carcinoma.

Inclusion: Male or female, age ≥ 18 years old; Advanced clear cell renal cell carcinoma confirmed by histology or cytology and not amenable to curative surgery; Has not received any previous systemic anti-tumor treatment for advanced renal cell carcinoma; Expected survival period is at least 3 months; ECOG performance status of 0 or 1, or KPS score of at least 70; Has measurable disease per RECIST 1.1; Organ function should meet the following criteria:; Absolute neutrophil count (ANC) ≥ 1.5×10\^9/L; Platelet (PLT) ≥90×10\^9/L; Hemoglobin (Hb) ≥ 90 g/L (no blood transfusion or hematopoietic stimulator treatment within 7 days); Albumin ≥ 30 g/L; Total bilirubin ≤1.5×ULN (for subjects with Gilbert's syndrome, it can be ≤3×ULN); ALT and AST ≤1.5×ULN (If liver metastasis is combined, ALT and AST≤3×ULN); Creatinine (Cr) ≤1.5 × ULN; Creatinine clearance (Ccr) (to be calculated only when Cr > 1.5× ULN) > 50 ml/min (Cockcroft-Gault formula); Activated partial thrombin time (APTT) ≤1.5×ULN, International normalized ratio (INR) ≤1.5×ULN; Voluntarily sign the informed consent form, understand the study and be willing to follow the protocol and complete all experimental procedures.

Exclusion: Received prior antineoplastic therapy (including chemotherapy, biologic therapy, immunotherapy, or Chinese traditional medicines with antitumor indications) before the first dose of study treatment; Has received major surgery (grade 3 or 4 as defined in the Measures for the Administration of Clinical Application of Medical Technology) within 28 days before the first dose of study treatment and has not yet recovered from which; or any planned curative surgery for renal cell carcinoma during the study; Clinically significant gastrointestinal abnormalities such as malabsorption syndrome, major gastric or small-bowel resection that may affect drug absorption, active peptic ulcer disease, inflammatory bowel disease, ulcerative colitis, or other conditions increasing the risk of perforation; or history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 28 days before the first dose of study treatment; Systemic corticosteroids (>10 mg/day prednisone or equivalent) or other immunosuppressive agents required within 2 weeks before the first dose or anticipated during study treatment, except for:; Topical, intranasal, or inhaled corticosteroids; Corticosteroids as premedication for infusion-related or hypersensitivity reactions (e.g., premedication for CT imaging); Replacement therapy such as levothyroxine, insulin, or physiologic corticosteroid replacement for adrenal or pituitary insufficiency; Low-dose corticosteroids for orthostatic hypotension; Prior organ transplant, except corneal transplant; prior allogeneic stem-cell transplant; Interstitial lung disease or non-infectious pneumonitis that is currently symptomatic or has previously required systemic corticosteroids, in the opinion of the investigator likely to interfere with toxicity assessment or management; Any severe, progressive, or uncontrolled medical condition that, in the investigator's judgment, makes the subject unsuitable for the study, including but not limited to:; Infection requiring systemic therapy; Symptomatic pleural, pericardial, or ascitic fluid requiring or having undergone drainage within 2 weeks before the first dose (minimal asymptomatic effusion, third-spacing due to hypoalbuminaemia, or cases where benefit outweighs risk may be allowed); History of coagulopathy (e.g., deep-vein thrombosis) or severe bleeding diathesis; clinically significant bleeding event (e.g., gastrointestinal bleeding) within 1 month before the first dose; History of severe psychiatric disorder; Any other condition that, in the investigator's opinion, renders study participation riskier than beneficial; Prior grade 3-4 immune-related adverse events that, in the investigator's judgment, should be excluded; Severe allergic or hypersensitivity disorders, significant drug allergies (including to investigational agents), or known hypersensitivity to any component of the study drug, including severe reactions to monoclonal antibodies; Participation in another clinical trial and receipt of an investigational agent within 28 days before the first dose of study treatment; Live vaccine received within 30 days before the first dose, or planned during the study or within 1 month after the last dose; History of another malignancy within 5 years before the first dose of study treatment, except for Lung carcinoma in situ, low-risk early-stage prostate cancer, or cured basal-cell carcinoma, squamous-cell carcinoma of the skin, cervical carcinoma in situ, or papillary thyroid carcinoma; Hepatitis B surface antigen (HBsAg) positive with HBV DNA >500 IU/mL or >2,500 copies/mL, or hepatitis C antibody positive with detectable HCV RNA, or known HIV infection, or active tuberculosis; Any other condition or circumstance that, in the investigator's opinion, unsuitable for participation; Clinically significant cardiovascular or cerebrovascular disease documented by any of the following:; Ischemic stroke (excluding silent lacunar infarction) or severe thromboembolic event within 6 months before the first dose of study treatment; Myocardial infarction, unstable angina, congestive heart failure, or clinically significant arrhythmia within 6 months before the first dose of study treatment; New York Heart Association (NYHA) class ≥ II heart failure before the first dose of study treatment; QTcF interval >450 ms (men) or >470 ms (women) before the first dose of study treatment; Left-ventricular ejection fraction (LVEF) ≤50 % before the first dose of study treatment; Documented central nervous system metastases; Clinically significant organ dysfunction or comorbidity likely to interfere with protocol adherence; Pregnant or breast-feeding women (women who agree to discontinue breast-feeding before signing informed consent may be enrolled).

ClinicalTrials.gov NCT07087158